What's breaking now, across thousands of outlets.
Microsoft is betting that its custom chips can lower costs, but the AI equation is more complicated than that.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
AMA CEO John Whyte, M.D., told Fierce Healthcare the increasing use of AI in clinical functions is “raising urgent questions about clinical authority, oversight and accountability.”
Oxylabs, Decodo, Webshare, ScrapingBee, and Honeygain are now one $3.6 billion family called Source, and it says AI agents have quadrupled demand.
For JPMorgan, the upside potential appears greater than the downside risk.
And there’s no opt-out available.
“Earnings disappointments by AI developers could undermine expectations of future profitability, dealing a hit to equity prices,” IMF Managing Director Kristalina Georgieva said.
The extraordinary disclosure — which does not name the AI providers or Indian organisations involved — comes as a result of proactive disclosures from the agents’ own developers, says CERT-In
